Browsing: Mortality Risk
Longevity and Mortality Investor’s coverage of bulk purchase annuity transactions. We are a leading source globally for mortality risk analysis, commentary and insights.
Recent months have delivered two significant developments that could profoundly impact life expectancy for those with chronic kidney disease.
As our population ages, the significance and frequency of falls increases. This affects life expectancy as well as morbidity and mortality.
Many firms maintain a longevity risk capital model, making sure the methodology remains relevant and proportionate to the risk. We shine a spotlight on these models here, considering how they may evolve with post-pandemic data and Solvency II reforms.
Those advising insurance companies and pension schemes on mortality are paying very close attention to developments with anti-obesity medicines.
Reverse mortgage securitisation activity is set to pick up in the coming years.
Demand for balance sheet solutions from insurers and supply of capital from asset managers provide market with solid fundamentals to maintain recent activity.
The outlook for metastatic melanoma continues to improve, driven by advancements in therapeutic strategies and ongoing research.
Arguably, the US life insurance industry had a strong 2023 from a balance sheet perspective. Asset growth outpaced liability growth, and policy reserves grew as well and the legacy of the Covid-19 pandemic would appear to be diminishing.
Life Risk News Q&A: Cobus Daneel, Chair, Continuous Mortality Investigation Projections Committee, shares what is top of mind in the mortality actuarial world as we look ahead to 2025.
Farsight Partners has finalised an agreement with funds managed by AB CarVal to source and advise on up to $1bn of transactions.